Sorafenib in Treating Patients With Metastatic, Locally Advanced, or Recurrent Sarcoma
Status:
Completed
Trial end date:
2011-03-01
Target enrollment:
Participant gender:
Summary
This phase II trial is studying how well sorafenib works in treating patients with
metastatic, locally advanced, or recurrent sarcoma. Sorafenib may stop the growth of tumor
cells by blocking some of the enzymes needed for cell growth and by blocking blood flow to
the tumor.